Abstract
The legal and economic environment of the pharmaceuticals industry is analyzed in the context of the development of national and international legal standards for the protection of intellectual property. Empirical studies on the relationship between intellectual property laws and economic growth are used to examine the actual outcomes under differing approaches to legal protections for the industry in two countries.